Skip to main content
. Author manuscript; available in PMC: 2014 Dec 28.
Published in final edited form as: J Control Release. 2013 Oct 2;172(3):1045–1064. doi: 10.1016/j.jconrel.2013.09.026

Fig. 20.

Fig. 20

CALAA-01. Size: about 70 nm. Binding site: Transferrin receptor. Currently in phase I of FDA clinical trials. Seeking indication for solid tumors. The recommended dose is 18–30 mg siRNA/m2. Developed by Calando Pharmaceuticals, Inc.